Literature DB >> 2225796

A novel immunoassay for the quantitation of human C4 gene products.

J M Moulds1, F C Arnett, C G Giles, R G Hamilton.   

Abstract

Utilizing mouse monoclonal antibodies which recognize Rodgers 1 and Chido 1 epitopes carried on the C4A and C4B molecules, and heat-aggregated IgG to activate C1, an immunoassay was developed for the quantitation of total C4 as well as C4A and C4B. Interassay variation was 12.4, 11.5 and 10.8%, respectively. The immunoassay was compared to the quantitation of total C4 by radial immunodiffusion by testing 103 random white controls and gave a Pearson's product-moment correlation coefficient of 0.81. Three genetic total-C4-deficient individuals were nonreactive in all three assays. This activated assay is specific, reproducible, and superior to existing methods for the quantitation of C4A and C4B and detection of the heterozygous C4 null state.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225796     DOI: 10.1159/000463134

Source DB:  PubMed          Journal:  Complement Inflamm        ISSN: 1012-8204


  3 in total

1.  Effects of C4 null alleles and homoduplications on quantitative expression of C4A and C4B.

Authors:  A Hammond; W Ollier; M J Walport
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex.

Authors:  Erwin K Chung; Yan Yang; Robert M Rennebohm; Marja-Liisa Lokki; Gloria C Higgins; Karla N Jones; Bi Zhou; Carol A Blanchong; C Yung Yu
Journal:  Am J Hum Genet       Date:  2002-09-11       Impact factor: 11.025

3.  Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease.

Authors:  C A Blanchong; B Zhou; K L Rupert; E K Chung; K N Jones; J F Sotos; W B Zipf; R M Rennebohm; C Yung Yu
Journal:  J Exp Med       Date:  2000-06-19       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.